Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

EP: 1.Overview of Current ADCs in Breast Cancer

EP: 2.ADCs in Breast Cancer: Mechanism of Action, and Components

EP: 3.Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

EP: 4.Expert Perspectives on the Management of SG-Related Neutropenia

EP: 5.Navigating SG-related Diarrhea

EP: 6.Expert Insights: SG Adverse Events Management including Alopecia & Nausea

EP: 7.Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

EP: 8.Clinical Management Considerations: Pneumonitis associated with T-DXd

Now Viewing

EP: 9.Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

EP: 10.Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

EP: 11.Future Perspectives on ADCs in Breast Cancer

EP: 12.Expert Insights: Investigational ADCs Safety Profiles

EP: 13.Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

In terms of pneumonitis and cardiotoxicity, is your management and monitoring relatively the same to trastuzumab deruxtecan (T-DXd)?

• What other pertinent adverse effects (AEs) of trastuzumab emtansine (T-DM1) should practicing oncologists be aware of?

1. Peripheral neuropathy
2. Thrombocytopenia
3. Aspartate aminotransferase/alanine aminotransferase elevations

• Let’s dive deeper into managing some of these T-DM1–related AEs; how do you manage the following:

1. Peripheral neuropathy
2. Thrombocytopenia: When do you delay/hold/discontinue therapy?
3. Hepatotoxicity: When do you delay/hold/discontinue therapy?

Please comment on any other treatment-resistant AEs with T-DM1 seen in your clinical practice.